Samsung Biologics Co., Ltd. (207940) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Samsung Biologics Co., Ltd. (207940:KRX), powered by AI.
- Current Price
- ₩1,332,000
- P/E Ratio
- 34.6
- Market Cap
- 61.7T
- Sector
- Healthcare
What is the Samsung Biologics Co., Ltd. stock price forecast?
Samsung Biologics Co., Ltd. is currently trading at ₩1,332,000. View real-time AI analysis on Alpha Lenz.
What is Samsung Biologics Co., Ltd. insider trading activity?
View the latest insider trading data for Samsung Biologics Co., Ltd. on Alpha Lenz.
What is Samsung Biologics Co., Ltd.'s P/E ratio?
Samsung Biologics Co., Ltd.'s P/E ratio is 34.6.
Samsung Biologics Co., Ltd.
KRX · 207940“Samsung Biologics Co., Ltd. trades at a P/E of 34.6 (premium valuation) with strong ROE of 19.4%. 3Y revenue CAGR of 14.9% highlights clear growth momentum.”
Ask for details →Company Overview
Samsung Biologics Co., Ltd. is a key player in the biopharmaceutical manufacturing and services industry. Established as a subsidiary of Samsung Group, it focuses on the development and manufacturing of biologic drugs. The company provides contract development and manufacturing organization (CDMO) services, supporting pharmaceutical companies in bringing innovative treatments to market efficiently. Samsung Biologics operates through state-of-the-art facilities offering comprehensive services from cell line development to large-scale manufacturing, impacting the healthcare and biotechnology sectors significantly. Headquartered in South Korea, it plays a critical role in the global supply chain of biologics, an essential component in treating complex diseases like cancer and autoimmune disorders. The company's strategic partnerships and investments in advanced bioprocessing technologies enhance its market position as a leader in its field.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Samsung Biologics Co., Ltd. trades at a P/E of 34.6 (premium valuation) with strong ROE of 19.4%. 3Y revenue CAGR of 14.9% highlights clear growth momentum.”
Ask for details →Frequently Asked Questions
Samsung Biologics Co., Ltd. (ticker: 207940) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 5,047 employees. Market cap is $61.7T.
The current price is ₩1,332,000 with a P/E ratio of 34.56x and P/B of 8.28x.
ROE is 19.44% and operating margin is 45.41%. Annual revenue is $4.6T.